Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsChild and adolescent psychiatry — disruptive behaviour

Psych MEQs / SAQs · Child and adolescent psychiatry — disruptive behaviour

Conduct and oppositional disorders — multi-domain assessment and stepped care (MEQ)

FRANZCP-style MEQ on ODD/CD: assessment, Moffitt pathways, parent training and MST, limited pharmacotherapy, ASPD trajectory counselling.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 12-year-old boy is referred after repeated school suspensions for arguing with teachers, leaving class, and fighting. Parents report chronic defiance since early primary school, lying about homework, and recent shoplifting with older peers. He is restless and inattentive; Conners teacher ratings suggest ADHD. There is harsh, inconsistent discipline at home and maternal depression. He denies remorse about the fight that injured a peer's lip. There is no clear manic episode. (i) Outline multi-informant assessment priorities including ODD vs CD discrimination, CU features, comorbidity and risk. (ii) Formulate using developmental pathway language (e.g. Moffitt) and family coercive processes. (iii) Give a stepped psychosocial plan including a named parenting approach and when MST would be considered. (iv) State the limited role of medication, including ADHD treatment priority and monitoring if an antipsychotic is used for severe aggression. (v) Discuss prognosis and adult ASPD risk communication with the family. (20 marks)

Model answer

Reveal model answer

(i) Assessment. Multi-informant history (child, parents, school, any youth justice/welfare). Map DSM ODD domains and CD criterion groups with timelines and settings; note childhood-onset features (defiance from early primary) and emerging CD behaviours (fighting with injury, shoplifting). Assess limited prosocial emotions / CU features (remorse, empathy, shallow affect, concern about performance) across relationships. Screen ADHD (restlessness, inattention, multi-setting ratings), learning, mood, anxiety, substances, trauma. Risk: violence recurrence, peer harm, absconding, exploitation, home safety, self-harm. Parenting style, maternal depression, peer network. Capacity/consent and mandatory reporting principles (jurisdiction-specific).[2][6]

(ii) Formulation. Likely childhood-onset disruptive pathway with ADHD comorbidity and coercive family cycle, now escalating via antisocial peers — closer to life-course-persistent risk than pure adolescence-limited delinquency, especially if CU features are confirmed. Not mania. Strengths and protective factors must also be listed for balanced formulation.[1][6]

(iii) Psychosocial plan. Psychoeducation; behavioural parent management training (clear commands, praise, consistent consequences; address maternal depression referral); school behaviour plan and attendance recovery; peer-network change work. If multi-domain severe CD with justice risk persists, consider MST-level ecological intensity (home-based, caregivers as change agents, fidelity-based) where available.[3][4]

(iv) Medication. Optimise ADHD treatment first if ADHD confirmed. No antipsychotic for defiance alone. If severe residual aggression after psychosocial work, specialist time-limited low-dose risperidone pathway with weight/metabolic/EPS/prolactin monitoring and explicit review date (guideline-aligned adjunctive use).[5]

(v) Prognosis talk. Elevated adult antisocial/SUD risk with early-onset CD, CU traits, ADHD and adversity — but not inevitable ASPD; ASPD is an adult diagnosis. Emphasise treatable drivers (parenting, ADHD, peers, school) and hope for desistance with sustained multiagency work.[1][7]

Common errors

  • Equating ODD with CD or diagnosing ASPD in a child.
  • Starting risperidone before parent training and ADHD assessment.
  • Ignoring school and peer ecology.
  • Absolute hopelessness or absolute reassurance about adult outcomes. [2][5]

Examiner notes

Reward named interventions (PMT, MST), CU specifier language, and explicit monitoring if medication is mentioned. Penalise vague "family therapy" without behavioural content. [2][4][5]

References

  1. [1]Moffitt TE Adolescence-limited and life-course-persistent antisocial behavior: a developmental taxonomy Psychol Rev, 1993.PMID 8255953
  2. [2]Steiner H, Remsing L Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder J Am Acad Child Adolesc Psychiatry, 2007.PMID 17195736
  3. [3]Scott S, Spender Q, Doolan M, et al. Multicentre controlled trial of parenting groups for childhood antisocial behaviour in clinical practice BMJ, 2001.PMID 11473908
  4. [4]Henggeler SW, Schaeffer CM Multisystemic Therapy: Clinical Overview, Outcomes, and Implementation Research Fam Process, 2016.PMID 27370172
  5. [5]Gorman DA, Gardner DM, Murphy AL, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder Can J Psychiatry, 2015.PMID 25886657
  6. [6]Frick PJ, White SF Research review: the importance of callous-unemotional traits for developmental models of aggressive and antisocial behavior J Child Psychol Psychiatry, 2008.PMID 18221345
  7. [7]Robins LN Deviant children grown up Eur Child Adolesc Psychiatry, 1996.PMID 9010663